55 results about "Prohormone Convertases" patented technology

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The present disclosure relates to small molecule inhibitors of proprotein convertase subtilisin-like / kexin type 9 (PCSK9) pharmaceutical compositions comprising said compounds and their use in prevention and treatment of diseases and conditions associated with PCSK9.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a biomarker in preparation of a product for diagnosing sepsis, the biomarker is proprotein convertase subtilisin 6 (PCSK6), and the biomarker has remarkably high sensitivity and specificity in the aspect of sepsis diagnosis.

The present disclosure relates to small molecule inhibitors of proprotein convertase subtilisin-like / kexin type 9 (PCSK9), pharmaceutical compositions comprising said compounds, and their use in the prevention and treatment of diseases and disorders associated with PCSK9.

The present invention belongs to the field of biomedical technologies, and specifically relates to the use of a biomarker in the preparation of a product for diagnosing sepsis. The biomarker is proprotein convertase subtilisin / kexin type 6 (PCSK6), which has significantly high sensitivity and specificity in diagnosing sepsis.

This invention discloses the application of a polypeptide in inhibiting inflammatory pain, belonging to the field of biomedicine. The polypeptide is Mexneurin-3 (Mx-3), one of three Mexneurin polypeptides formed by the cleavage of ProMexneurin, a protein precursor found in the mammalian central nervous system, by proprotein convertase. This invention reveals that Mx-3, as an endogenous polypeptide, has significant analgesic effects, inhibiting both acute and chronic inflammatory pain with fewer side effects and greater safety. This invention also elucidates the analgesic mechanism of Mx-3, finding that it upregulates diacylglycerol (DAG) levels in the spinal cord and activates protein kinase C (PKC). The application of Mx-3 in inhibiting inflammatory pain provided by this invention can be used to develop safer and more effective novel analgesics, providing new ideas and references for the treatment of inflammatory pain.

The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).

The present invention relates to a method of reducing low density lipoprotein cholesterol or preventing a cardiac event in a subject at risk of having an atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease, comprising administering to the subject a prophylactically effective amount of an RNAi agent. In addition, the present invention relates to a method of preventing the development of an atherosclerotic cardiovascular disease in a subject, comprising administering to the subject a prophylactically effective amount of an RNAi agent. Furthermore, the present invention relates to a method of treating a subject at risk of having an atherosclerotic cardiovascular disease or equal to an atherosclerotic cardiovascular disease, comprising administering to the subject a therapeutically effective amount of an RNAi agent.

Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guid

The invention relates to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.

The present invention relates to a dual-targeting siRNA agent, which comprises two different siRNAs targeting two different genes or pharmaceutically acceptable salts thereof, and the two different siRNAs or salts thereof are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand. The two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of a drug for preventing or treating diseases related to hypertension or / and lipid disorders. The dual-targeting siRNA agent of the present invention can effectively inhibit the expression of two target genes in vivo simultaneously, and has the advantages of strong non-antagonistic activity and high safety. The present invention also provides siRNAs corresponding to the genes of the above dual-targeting siRNA agent and their use for preventing or treating diseases related to hypertension or / and lipid disorders.

To provide: an siRNA which inhibits proprotein convertase subtilisin / kexin type 9 (PCSK9) gene expression; a pharmaceutical composition containing the siRNA; and a conjugate.SOLUTION: Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains a nucleotide sequence I, the nucleotide sequence I having the same length as a specific nucleotide sequence 1, with three or less nucleotide differences. The antisense strand contains a nucleotide sequence II, the nucleotide sequence II having the same length as another specific nucleotide sequence 2, with three or less nucleotide differences. The siRNA, pharmaceutical composition thereof and the conjugate can effectively treat and / or prevent hypercholesterolemia.SELECTED DRAWING: Figure 3

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The present invention relates to a dual-targeting siRNA agent comprising two distinct siRNAs targeting two different genes or their pharmaceutically acceptable salts, wherein the two distinct siRNAs or their salts are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand, and the two different genes are selected from a group consisting of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and human angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of drugs for preventing or treating diseases associated with hypertension and / or dyslipidemia. The dual-targeting siRNA agent described in the present invention can effectively inhibit the expression of two target genes simultaneously in vivo, offering the advantages of strong non-antagonistic activity and high safety. The present invention also provides the siRNAs targeting corresponding genes for the aforementioned dual-targeting siRNA agent and their use for preventing or treating diseases associated with hypertension and / or dyslipidemia.

Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and / or for the treatment and / or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention relates to a dual-targeting siRNA agent, which comprises two different siRNAs targeting two different genes or pharmaceutically acceptable salts thereof, the two different siRNAs or salts thereof are connected through pharmaceutically acceptable ligands, the s-RNA is dsRNA composed of a sense strand and an antisense strand, and the s-RNA is dsRNA composed of a positive-sense strand and a negative-sense strand. The two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin 9 (PCSK9) and human angiopoietin-like protein 3 (ANGPTL3). The invention provides application of the dual-targeting s iRNA agent in preparation of drugs for preventing or treating diseases related to hypertension or / and lipid disorder. The dual-targeting siRNA agent can effectively inhibit expression of two target genes in vivo at the same time, and has the advantages of being high in mutual non-antagonistic activity and high in safety. The invention also provides the s iRNA of the corresponding gene of the dual-targeting s iRNA agent and application of the s iRNA to prevention or treatment of diseases related to hypertension or / and lipid disorder.

This invention relates to compounds of Formula I and their isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs. The compounds of Formula I can be used as inhibitors of proprotein convertase subtilisin 9 (PCSK9), effectively inhibiting PCSK9 activity and reducing the concentration of low-density lipoprotein cholesterol in plasma, and have good application prospects in the preparation of drugs for the treatment or prevention of cardiovascular diseases.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin / Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

The present disclosure provides compositions and methods for modifying the PCSK9 gene. In some aspects, the disclosure provides a guide RNA, compositions thereof, and pharmaceutical compositions comprising guide RNAs or compositions as described herein. In some aspects, the disclosure also provides uses and methods of use of guide RNAs, compositions or pharmaceutical compositions thereof, as described herein, the present invention relates to a PCSK9 inhibitor for inducing a double-strand break or a single-strand break in the PCSK9 gene, for reducing expression of the PCSK9 gene in a cell or subject, and for treating a patient suffering from or at risk of suffering from a PCSK9-related disease or condition.

Provided herein are gene repressor systems comprising a fusion protein, such as a fusion protein comprising a DNA binding domain, such as TALE, a zinc finger, or a CRISPR protein of catalyzed death, and a guide nucleic acid (gRNA) useful for repressing a proprotein convertase subtilisin / kexin type 9 (PCSK9) gene. Also provided are methods of using such systems to repress PCSK9 transcription.

The invention relates to the technical field of biomedical examination, and particularly discloses a proprotein convertase subtilisin / kexin type 9 standard product protective agent, a detection kit for determining proprotein convertase subtilisin / kexin type 9 and application of the detection kit. The protective agent is prepared from the following components in percentage by weight: 1 percent to 3 percent of protein, 0.5 percent to 2 percent of amino acid, 1 percent to 5 percent of a surfactant, 0.01 percent to 0.5 percent of an antioxidant, 0.01 percent to 0.2 percent of a de-foaming agent, 0.01 percent to 0.2 percent of EDTA (Ethylene Diamine Tetraacetic Acid), 0.05 percent to 0.2 percent of a preservative and the balance of a buffer solution. The proprotein convertase subtilisin / kexin type 9 standard product protective agent provided by the invention can significantly improve the stability of the proprotein convertase subtilisin / kexin type 9, prolong the effective period of the detection reagent, and ensure the accuracy and repeatability of the detection result. The detection kit provided by the invention is short in detection time, good in precision, high in sensitivity and good in reagent uniformity.

The present application relates to the field of biomedical testing technology and specifically discloses a protective agent for proprotein convertase subtilisin 9 standard sample, a detection kit for measuring proprotein convertase subtilisin 9, and its application. The protective agent comprises the following components in weight percentage: 1 wt% to 3 wt% protein, 0.5 wt% to 2 wt% amino acid, 1 wt% to 5 wt% surfactant, 0.01 wt% to 0.5 wt% antioxidant, 0.01 wt% to 0.2 wt% defoaming agent, 0.01 wt% to 0.2 wt% EDTA, 0.05 wt% to 0.2 wt% preservative, and the remainder being buffer. The protective agent for proprotein convertase subtilisin 9 standard sample provided herein can significantly improve the stability of proprotein convertase subtilisin 9, extend the shelf life of the detection reagent, and ensure the accuracy and reproducibility of the test results. The detection kit provided herein also has a short detection time, good precision, high sensitivity, and good reagent uniformity.

A low-molecular weight compound having an activity of inhibiting the functions of proprotein convertase subtilisin / kexin type 9 (PCSK9), a PCSK9 inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, and a medicament containing the PCSK9 inhibitor as an active component for use in prevention or treatment of one or more symptoms, diseases, or disorders, related to the functions of PCSK9.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and / or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and / or MODS, and methods of detecting Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) and / or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.

An siRNA which inhibits proprotein convertase subtilisin / kexin type 9 (PCSK9) gene expression, a pharmaceutical composition containing the siRNA, and a conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I; nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotides differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotides differences. The siRNA, pharmaceutical composition thereof and the conjugate can effectively treat and / or prevent hypercholesterolemia.